SCHEMBL4891990

SCHEMBL4891990

COC(=O)c1ccc(CC2CNC(=O)N2Cc2ccc(CP(=O)(OF)OF)c(Br)c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 4/20 0.37
HIF1A Q16665 1/20 0.37
ALDH1A1 P00352 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CCR6 P51684 1/20 0.34
HKDC1 Q2TB90 1/20 0.34
USP2 O75604 1/20 0.34
HDAC8 Q9BY41 3/20 0.34
HDAC6 Q9UBN7 3/20 0.34
HDAC2 Q92769 2/20 0.34
HDAC1 Q13547 1/20 0.34
RAB9A P51151 2/20 0.33
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32
MCHR1 Q99705 1/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4901558 0.90 HDAC8 (0.35) MAPK10ALDH1A1HDAC8HDAC6HDAC2
SCHEMBL4901226 0.79 MAPK10 (0.46) MAPK10HIF1AALDH1A1CCR6HKDC1
SCHEMBL4899408 0.76 HDAC1 (0.42) MAPK10ALDH1A1HDAC8HDAC6HDAC1
SCHEMBL4901455 0.75 MAPK10 (0.37) MAPK10HIF1AALDH1A1MEN1KMT2A
SCHEMBL4891983 0.75 MAPK10 (0.37) MAPK10HIF1AALDH1A1MEN1KMT2A
SCHEMBL4891992 0.73 MAPK10 (0.39) MAPK10HIF1AALDH1A1CCR6HKDC1
SCHEMBL4890554 0.72 MAPK10 (0.38) MAPK10HIF1AALDH1A1CCR6HKDC1
SCHEMBL4899314 0.71 MAPK10 (0.37) MAPK10HIF1AALDH1A1CCR6HKDC1
SCHEMBL4895554 0.71 MAPK8 (0.43) MAPK10HIF1AALDH1A1MEN1KMT2A
SCHEMBL4900023 0.71 MAPK10 (0.40) MAPK10HIF1AALDH1A1USP2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed
WO-2006078698-A1 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases PPM1B, PPM1D, PTPRS MAPK10 656/4885HIF1A 1650/4885ALDH1A1 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.